MARKET

BVXV

BVXV

Biondvax Pharmac
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.300
+0.040
+3.17%
After Hours: 1.310 +0.01 +0.77% 16:08 05/26 EDT
OPEN
1.230
PREV CLOSE
1.260
HIGH
1.310
LOW
1.210
VOLUME
42.56K
TURNOVER
0
52 WEEK HIGH
4.190
52 WEEK LOW
1.000
MARKET CAP
24.21M
P/E (TTM)
-1.4305
1D
5D
1M
3M
1Y
5Y
BiondVax to Present at H.C. Wainwright Global Investment Conference
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will...
PR Newswire · 05/19 15:17
BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies Program
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced that Dr. Tamar Ben...
PR Newswire · 05/12 10:30
BiondVax to Present at this week's Biomed Israel Conference
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will...
PR Newswire · 05/09 10:00
BVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies…
By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Definitive Collaboration Agreement for Pipeline of Nanosized Antibodies (NanoAbs) On March 24, 2022, BiondVax Pharmacueticals Ltd. (NASDAQ:BVXV) announced a definitive colla...
Zacks Small Cap Research · 05/02 14:15
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 04/19 13:06
BiondVax to host a Hebrew-language analyst and investor webinar on April 6th
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that the Com...
PR Newswire · 04/05 10:49
BiondVax to host analyst and investor webinar on April 4th
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that the Com...
PR Newswire · 03/31 20:00
Companhia Energetica, Canopy Growth, Tilray Brands among premarket losers' pack
Clever Leaves Holdings (CLVR) -20% after sharp rally last week. Companhia Energetica (CIG) -15%. BiondVax Pharmaceuticals (BVXV) -9% on FY earnings release. Enservco (ENSV) -8% announces to amend its Financial Statements for First, Second
Seekingalpha · 03/28 12:23
More
No Data
Learn about the latest financial forecast of BVXV. Analyze the recent business situations of Biondvax Pharmac through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BVXV stock price target is 9.50 with a high estimate of 12.00 and a low estimate of 7.00.
High12.00
Average9.50
Low7.00
Current 1.300
EPS
Actual
Estimate
-0.22-0.16-0.11-0.05
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 18
Institutional Holdings: 363.91K
% Owned: 1.95%
Shares Outstanding: 18.63M
TypeInstitutionsShares
Increased
3
29.25K
New
4
131.28K
Decreased
2
2.06K
Sold Out
7
76.98K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Chairman/Director
Mark Germain
Chief Executive Officer/Director
Amir Reichman
Chief Financial Officer
Uri Ben-Or
Chief Operating Officer
Elad Mark
Chief Scientific Officer
Tamar Ben-Yedidia
Other
Ester Abramov
Director
Isaac Devash
Director
George Lowell
Director
Samuel Moed
Director
Avner Rotman
Independent Director
Morris Laster
Non-Executive Independent Director
Yael Margolin
Non-Executive Independent Director
Adi Raviv
No Data
No Data
About BVXV
BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Webull offers kinds of Biondvax Pharmaceuticals Ltd - ADR stock information, including NASDAQ:BVXV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BVXV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BVXV stock methods without spending real money on the virtual paper trading platform.